title: Comparison of intralesional corticosteroid and propranolol treatment of periorbital infantile hemangiomas: an outcome study of 61 cases.
abstract: OBJECTIVE
  To compare intralesional corticosteroid (IC) injections with oral propranolol in children with periorbital infantile hemangioma (IH).
  
  
  METHODS
  Children were diagnosed with IH and treated with IC (n = 29) or propranolol (n = 14). In cases in which no further improvement was seen, treatment was stopped and the outcome measured. Type, duration, and complications of treatment and supportive or additional therapies were scored, along with outcomes of visual measurements, at the start and end of therapy.
  
  
  RESULTS
  Twenty-one of the 29 children (72%) treated with IC injections were given a second injection and 16 (55%) were given more than two. Median duration of IC therapy was 15.9 months (interquartile range (IQR) 10.28), compared with 6.5 months (IQR 4.87) for propranolol (p&lt;0.001). The complications reported after IC injections were bleeding (n = 9) and ulceration (n = 7). No complications were noted in the propranolol group. Additional therapy consisting of oral prednisolone therapy was applied in one child from the steroid-treated group. The levels of amblyopia and the median absolute improvement did not significantly differ between the groups.
  
  
  CONCLUSIONS
  The IC injections and oral propranolol medication equally improved amblyopia in children with IH of the periorbital and cheek region; however, propranolol was associated with fewer complications and additional or supportive treatment was not indicated. We prefer oral propranolol medication over IC injections in cases in which IH threatens to hamper visual acuity.
authors.affiliation: Department of Plastic and Reconstructive Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam - The Netherlands.
authors.forename: Marije J
authors.initials: MJ
authors.lastname: Hoornweg
authors.forename: Peerooz
authors.initials: P
authors.lastname: Saeed
authors.forename: Michael W T
authors.initials: MW
authors.lastname: Tanck
authors.forename: J Joris
authors.initials: JJ
authors.lastname: Hage
authors.forename: Adriaan D
authors.initials: AD
authors.lastname: Coumou
authors.forename: Chantal M A M
authors.initials: CM
authors.lastname: Van Der Horst
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005142:Eyelid Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006391:Hemangioma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008297:Male; D011239:Prednisolone / Q000008:administration & dosage*; D011433:Propranolol / Q000008:administration & dosage*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D005938:Glucocorticoids; D011239:Prednisolone; D011433:Propranolol